Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Savara Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
SVRA
Nasdaq
2836
www.savarapharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Savara Inc.
FDA Decision Watch: Capricor’s DMD Therapy Faces Make-Or-Break Decision, Savara’s Lung Disease Drug In The Spotlight This Week
- Nov 16th, 2026 3:09 am
Three FDA Decisions Loom After Summit’s Rejection — Capricor, Savara, Alzheimer’s Data Top Biotech’s Watchlist
- Nov 15th, 2026 7:25 pm
Savara Announces New Employment Inducement Grant
- Nov 12th, 2026 2:05 pm
Why Did Insmed Stock Jump?
- Oct 30th, 2026 5:15 am
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
- Oct 21st, 2026 11:10 am
Will Long‑Term Molgramostim Data at CHEST 2026 Change Savara's (SVRA) Autoimmune PAP Narrative?
- Oct 13th, 2026 2:14 am
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
- Oct 12th, 2026 2:05 pm
Savara Has Lost 30% Since December: JPMorgan Sees 146% Upside
- Oct 11th, 2026 10:43 am
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
- Aug 24th, 2026 2:05 pm
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
- Aug 11th, 2026 2:05 pm
What Insmed Stock's Premium Is Actually Buying
- Aug 7th, 2026 9:39 am
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
- Jul 30th, 2026 6:05 am
Here's Why You Should Add Savara Stock to Your Portfolio Now
- Jul 22nd, 2026 7:21 am
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
- Jun 27th, 2026 9:34 am
Savara Announces Chief Financial and Administrative Officer Transition
- Jun 8th, 2026 2:05 pm
Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns
- Jun 8th, 2026 11:13 am
Scroll